| PR3-ANCA (N = 9) | MPO-ANCA (N = 6) | PR3 + MPO (N = 1) | |
---|---|---|---|---|
ACR criteria | Â | Â | Â | |
1 item | abnormal chest radiograph | 0 | 3 (50Â %) | 0 |
2 items | purulent/bloody nasal discharge + granuloma formation | 2 (22 %) | 1 (17 %) | 0 |
 | abnormal chest radiograph + abnormal urinary sediment | 1 (11 %) | 1 (17 %) | 1 (100 %) |
3 items | purulent/bloody nasal discharge + abnormal chest radiograph + granuloma formation | 3 (33 %) | 0 | 0 |
 | abnormal chest radiograph + abnormal urinary sediment + granuloma formation | 1 (11 %) | 0 | 0 |
 | purulent/bloody nasal discharge + abnormal chest radiograph + abnormal urinary sediment | 2 (22 %) | 1 (17 %) | 0 |
CHCC criteria | Â | Â | Â | |
0 item | Â | 4 (44Â %) | 6 (100Â %) | 1 (100Â %) |
1 item | granuloma formation | 0 | 0 | 0 |
 | necrotizing vasculitis | 2 (22 %) | 0 | 0 |
2 items | granuloma formation + necrotizing vasculitis | 3 (33 %) | 0 | 0 |
Surrogate marker | Â | Â | Â | |
 fixed pulmonary infiltrates, nodules, or cavitations (>1 month) | 7 (78 %) | 5 (86 %) | 1 (100 %) | |
 bronchial stenosis | 3 (33 %) | 3 (50 %) | 1 (100 %) | |
 bloody nasal discharge and crusting (>1 month), or nasal ulceration | 4 (44 %) | 0 | 0 | |
 chronic sinusitis, otitis media, or mastoiditis (>3 months) | 5 (56 %) | 4 (67 %) | 1 (100 %) | |
 retro-orbital mass or inflammation (pseudotumour) | 2 (22 %) | 0 | 0 | |
 saddle nose deformity/destructive sinonasal disease | 1 (11 %) | 0 | 0 |